MorphoSys AG (MOR ፦ ) የአክሲዮን ዋጋ እና ዜና

(EUR)	ማርች 2024	ከዓመት ዓመት ለውጥ
ገቢ	27.54 ሚ	13.11%
የሥራ ወጪ	289.14 ሚ	264.02%
የተጣራ ገቢ	-314.96 ሚ	-608.87%
የተጣራ የትርፍ ክልል	-1.14 ሺ	-526.67%
ገቢ በሼር	-8.27	-529.19%
EBITDA	-263.38 ሚ	-388.32%
ውጤታማ የግብር ተመን	0.51%	—

ቀሪ ሒሳብ ሉሆች

አጠቃላይ ንብረቶች

አጠቃላይ ተጠያቂነቶች

(EUR)	ማርች 2024	ከዓመት ዓመት ለውጥ
ጥሬ ገንዘብና የአጭር ጊዜ መዋዕለ ንዋይ	630.77 ሚ	-20.30%
አጠቃላይ ንብረቶች	1.83 ቢ	-17.85%
አጠቃላይ ተጠያቂነቶች	2.09 ቢ	-1.84%
አጠቃላይ እሴት	-261.67 ሚ	—
የሼሮቹ ብዛት	37.62 ሚ	—
የገበያ ዋጋ እና የተገለጸ ዋጋ	-9.72	—
የእሴቶች ተመላሽ	-34.27%	—
የካፒታል ተመላሽ	-41.11%	—

የገንዘብ ፍሰት

የተጣራ ዝርዝር ገንዘብ በጥሬ ገንዘብ

(EUR)	ማርች 2024	ከዓመት ዓመት ለውጥ
የተጣራ ገቢ	-314.96 ሚ	-608.87%
ከክወናዎች የተገኘ ጥሬ ገንዘብ	-71.53 ሚ	14.27%
ገንዘብ ከኢንቨስትመንት	28.62 ሚ	187.62%
ገንዘብ ከፋይናንስ	-950.28 ሺ	97.86%
የተጣራ ዝርዝር ገንዘብ በጥሬ ገንዘብ	-27.24 ሚ	75.37%
ነፃ የገንዘብ ፍሰት	246.91 ሚ	1,523.66%

ስለ

MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases. MorphoSys AG is listed on the Frankfurt Stock Exchange and on the US Nasdaq stock exchange. Novartis agreed to acquire the company in February 2024. Wikipedia

ዋና ሥራ አስፈጻሚ

Jean-Paul Kress

የተመሰረተው

1992

ዋና መሥሪያ ቤት

Planegg፣ ባቫሪያ
ጀርመን

ድህረገፅ

morphosys.com

ሠራተኞች

464